Amaya Lujambio Goizueta, PhD
About Me
Amaia Lujambio, PhD, is Assistant Professor, Oncological Sciences, a member of The Tisch Cancer Institute, and a member of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. Her research is focused on understanding the mechanisms of liver cancer initiation and liver cancer maintenance. Using a sophisticated precision mouse model of cancer, Dr. Lujambio is investigating biomarker-guided, precision therapies for hepatocellular carcinoma (HCC), the most common type of liver cancer. Her laboratory is also interested in the use of functional genomics for the identification of novel therapies and immunotherapies. Dr. Lujambio is the recipient of numerous honors and awards, including the Damon Runyan-Rachleff Innovation Award, NCI R37 Merit Award for Early State Investigators, and the GE Liver Junior Scientist Award.
Dr. Lujambio is on Twitter at @AmaiaLujambio
Language
English
Research Topics
Cancer, Epigenetics, Liver, Molecular Biology
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
Video
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Lujambio Goizueta has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.